公开(公告)号：WO2020072306A1

公开(公告)日：2020-04-09

申请号：PCT/US2019/053462

申请日：2019-09-27

Applicant: AMGEN INC.

Inventor： JAGANNATHAN, Bharadwaj ,  HUH, Joon ,  TREUHEIT, Michael ,  SHAN, Daxian

IPC: A61K9/00 ,  A61K9/08 ,  A61K9/16 ,  A61K9/19 ,  A61K39/00 ,  A61K39/395 ,  A61K47/00

Abstract: The invention disclosed herein relates to methods for reducing aggregation of bispecific antibodies, for example reducing aggregation of bispecific T cell engager (BiTE) antibody constructs, resulting from storage under frozen conditions by holding the antibodies at certain temperatures after thaw.

公开(公告)号：WO2018204907A1

公开(公告)日：2018-11-08

申请号：PCT/US2018/031347

申请日：2018-05-07

Applicant: AMGEN INC.

Inventor： ABEL, Jeff ,  CUI, Lingwen ,  GOSWAMI, Devrishi ,  HUH, Joon ,  JAGANNATHAN, Bharadwaj ,  KANAPURAM, Sekhar ,  MCAULEY, Arnold ,  SCHNEIDER, Michael ,  SETHURAMAN, Ananthakrishnan, G. ,  TREUHEIT, Michael ,  ZHANG, Jun

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/00

Abstract: The present invention provides an improved pharmaceutical composition for storage and administration comprising (a) a bispecific antibody construct comprising a first domain binding to a target cell surface antigen and a second domain binding to a second antigen, wherein the bispecific antibody construct is present at a concentration in the range from about 0.5 μg/ml to 20 mg/ml, (b) a preservative at a concentration effective to inhibit the growth of microbes, and (c) a diluent wherein bispecific antibody construct is stable and recoverable.

公开(公告)号：WO2018141910A1

公开(公告)日：2018-08-09

申请号：PCT/EP2018/052665

申请日：2018-02-02

Applicant: AMGEN RESEARCH (MUNICH) GMBH ,  AMGEN INC.

Inventor： MCAULEY, Arnold ,  GHATTYVENKATAKRISHNA, Pavan ,  ABEL, Jeff ,  HUH, Joon ,  POMPE, Cornelius ,  KANAPURAM, Sekhar ,  TREUHEIT, Michael ,  JAGANNATHAN, Bharadwaj

IPC: A61K39/395 ,  C07K16/28

Abstract: The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

公开(公告)号：WO2009015345A1

公开(公告)日：2009-01-29

申请号：PCT/US2008/071209

申请日：2008-07-25

Applicant: AMGEN INC. ,  TREUHEIT, Michael ,  RATNASWAMY, Gaya

Inventor： TREUHEIT, Michael ,  RATNASWAMY, Gaya

IPC: A61K9/06 ,  A61K9/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/48

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K39/39591 ,  A61K47/6835 ,  C07K16/00 ,  C07K2319/30

Abstract: The invention herein described provides, among other things: methods for making protein formulations based on isoelectric points; protein formulations made by the methods; and uses of the methods and of the protein formulations.

Abstract translation: 本文所述的本发明尤其提供了：基于等电点制备蛋白质制剂的方法; 蛋白质制剂的制备方法; 以及方法和蛋白质制剂的使用。